Quote:

---

Ohm is right, that past PRs have not moved the needle as much as they should

---

One of the big problems with PRs having little to no effect on share price is the paucity of data and the ineffective presentation. We still don't know exactly what the comparative drug for the mTNBC data was. Was it carboplatin alone, who knows?

If they're going to release topline data for NASH they should lay it out with the results for every endpoint and the biomarker results. It should look like a peer reviewed journal article but written so a wider audience can easily understand it.